Abstract
Purpose: Peroxiredoxins (PRDXs) are a family of antioxidant enzymes with six identified mammalian isoforms (PRDX1–6). PRDX expression is up-regulated in various types of solid tumors; however, individual PRDX expression, and its impact on prognostic value in ovarian cancer patients, remains unclear.Methods: PRDXs family protein expression profiles in normal ovarian tissues and ovarian cancer tissues were examined using the Human Protein Atlas database. Then, the prognostic roles of PRDX family members in several sets of clinical data (histology, pathological grades, clinical stages, and applied chemotherapy) in ovarian cancer patients were investigated using the Kaplan–Meier plotter.Results: PRDXs family protein expression in ovarian cancer tissues was elevated compared with normal ovarian tissues. Meanwhile, elevated expression of PRDX3, PRDX5, and PRDX6 mRNAs showed poorer overall survival (OS); PRDX5 and PRDX6 also predicted poor progression-free survival (PFS) for ovarian cancer patients. Furthermore, PRDX3 played significant prognostic roles, particularly in poor differentiation and late-stage serous ovarian cancer patients. Additionally, PRDX5 predicted a lower PFS in all ovarian cancer patients treated with Platin, Taxol, and Taxol+Platin chemotherapy. PRDX3 and PRDX6 also showed poor PFS in patients treated with Platin chemotherapy. Furthermore, PRDX3 and PRDX5 indicated lower OS in patients treated with these three chemotherapeutic agents. PRDX6 predicted a poorer OS in patients treated with Taxol and Taxol+Platin chemotherapy.Conclusion: These results suggest that there are distinct prognostic values of PRDX family members in patients with ovarian cancer, and that the expression of PRDX3, PRDX5, and PRDX6 mRNAs are a useful prognostic indicator in the effect of chemotherapy in ovarian cancer patients.
Highlights
Ovarian cancer is a leading cause of morbidity and mortality among women diagnosed with gynecologic malignancies, with ∼22,440 new cases and 14,080 cancer-related deaths each year in the United States [1]
Using the Human Protein Atlas database, we first analyzed the PRDXs protein expression in normal ovarian tissues and ovarian cancer tissues to determine the clinical relevance of PRDXs expression
We found that PRDX3 protein expression was not detected in normal ovarian tissues
Summary
Ovarian cancer is a leading cause of morbidity and mortality among women diagnosed with gynecologic malignancies, with ∼22,440 new cases and 14,080 cancer-related deaths each year in the United States [1]. The high ratio of death-to-incidence for women with ovarian cancer is mainly due to late-stage diagnosis. Many patients with ovarian cancer remain without symptoms until the disease reaches an advanced stage and it is exceedingly difficult to treat [2]. The primary role of these proteins is to protect cells from oxidative damage induced by cellular reactive oxygen species (ROS), which c 2018 The Author(s).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
